MeiraGTx (MGTX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does MeiraGTx (MGTX) do?
MeiraGTx Holdings plc (MGTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops genetic therapies for neurodegenerative disorders, ocular diseases, and salivary gland damage. The company builds proprietary synthetic riboswitch controls alongside integrated in-house viral vector manufacturing. It is worth $795.53M on the market and sold $401.78M over the last year.
- Market cap
- $795.53M
- P/E ratio
- 10.2×
- Annual sales
- $401.78M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 15, 2026
MGTX’s flags, in plain English
Each flag is a number from MeiraGTx’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Stupid Cash
Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 94.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 39.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Thinly Traded
Thinly traded, about 834 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about MGTX
How big is MeiraGTx?
MeiraGTx’s market cap is $795.53M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $401.78M: what customers paid the company over the last year, before any costs.
What is MGTX’s P/E ratio?
MGTX’s P/E ratio is 10.2×. Investors pay about 10.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with MGTX?
The company operates without commercial product sales and reports ongoing operating losses from clinical trial costs. That is one risk on MeiraGTx’s card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From MeiraGTx’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MGTX’s filings on SEC.gov. The Margin Monkey is research, not advice.
